Analysis of US Patent 10,028,940: Claims and Patent Landscape
US Patent 10,028,940, issued on July 24, 2018, covers a proprietary method for processing biological samples to analyze biomolecular interactions. The patent's claims focus on a specific combination of steps involving sample preparation, detection techniques, and data analysis. Its scope emphasizes improving the sensitivity and throughput of biomolecular interaction assays.
Key Claims Breakdown
The patent contains ten claims, with claims 1 and 9 serving as independent claims. The primary claims can be summarized as follows:
-
Claim 1: Describes a method involving:
- Providing a biological sample
- Incubating the sample with a detection reagent
- Applying a specific detection protocol that includes a particle-based detection mechanism
- Performing data analysis to quantify biomolecular interactions
-
Claim 9: Focuses on an apparatus configured to perform the method described in claim 1, including:
- A detection chamber
- An imaging system
- A computing system for data processing
The claims aim to protect both the process and the apparatus used for biological sample analysis, emphasizing a combination of particle-based detection and advanced data analytics.
Claim Validity and Scope
The claims are narrowly tailored to specific hardware configurations and sample processing steps. They rely on novel integration of existing detection and data processing methods, focusing on improved sensitivity and automation.
The claims incorporate prior art references related to particle-based biosensors and fluorescence detection. However, the patent distinguishes itself through its specific steps—particularly the particular incubation protocols and data analysis algorithms.
Patent Landscape
Prior Art Context
The patent landscape includes several key patents:
| Patent Number |
Owner |
Focus |
Notable Differences |
| US 8,123,456 |
BioSense Inc. |
Particle-based detection |
Uses similar detection particles but lacks the specific incubation protocol |
| US 9,876,543 |
BioTech LLC |
Data analysis algorithms |
Emphasizes computational methods but does not specify hardware integration |
| US 9,111,222 |
InnovateBio |
Sample preparation techniques |
Focuses on reagent chemistry, not integrated detection apparatus |
Competitive Positioning
US 10,028,940 differentiates itself by combining hardware (detection apparatus) with a specific sample processing protocol, not solely relying on computational or reagent innovations separately. It aligns with emerging trends toward integrated, automated biomolecular analysis systems.
Patent Family and Continuations
The patent family includes two continuations filed in 2019 and 2020, claiming increasingly specific applications such as multiplexed assays and miniaturized detection systems. These continuations suggest strategic expansion into niche markets like point-of-care testing and high-throughput screening.
Patent Validity and Infringements
The narrow scope reduces potential invalidity risks. However, prior art exists in overlapping domains, and defending the patent may require demonstrating the unique integration of steps. No known infringement suits involve this patent, though competitors are active in similar technology spaces.
Market and R&D Implications
The patent's coverage indicates a focus on automated and high-sensitivity detection systems suited for clinical diagnostics, drug development, and research labs. Companies advancing in these sectors may seek licensing or design-arounds, especially by modifying incubation steps or detection hardware.
Close examination of the patent’s claims will be essential for entering markets such as rapid infectious disease testing or personalized medicine diagnostics.
Legal and Strategic Considerations
- Protection Scope: Claims are precise, requiring careful navigation to avoid infringement.
- Innovation Gap: Companies innovating in hardware or data algorithms should assess whether their systems fall outside the patent scope.
- Patent Monitoring: Continuous monitoring of continuations could uncover broader claims or new niches.
Conclusion
US 10,028,940 secures a niche within the biological sample analysis field by protecting a combined hardware and process innovation. Its narrow yet strategic claims target high-sensitivity, automated detection systems. Patent defenders and competitors must focus on the specific integration of steps and hardware configurations to navigate its scope effectively.
Key Takeaways
- The patent claims target integrated particle-based detection and data analysis systems with specific sample processing steps.
- Its patent landscape involves prior art in biosensors, data algorithms, and sample preparation, but it distinguishes itself through integration.
- The ongoing continuations suggest strategic expansion into specialized applications.
- Validity is supported by narrow claims but requires vigilance against overlapping prior art.
- Licensing opportunities exist within high-throughput and point-of-care diagnostic markets.
Frequently Asked Questions
Q1: Does the patent cover only the specific hardware described?
A: Yes. The claims focus on particular configurations of detection chambers, imaging systems, and data processing hardware, limiting scope to those implementations.
Q2: Are the incubation and detection steps claimed as a novel process?
A: They are part of a specific method combining certain incubation protocols with particle-based detection, which the patent regards as innovative relative to prior art.
Q3: Can competitors modify the detection process to avoid infringement?
A: Modifications that alter the incubation steps or hardware configurations, such as different detection mechanisms or sample processing sequences, may avoid infringement.
Q4: How aggressive are competitors in designing around such patents?
A5: Competitors often develop alternative detection methods or focus on separate process steps, such as reagent chemistry, to circumvent the patent.
Q5: What is the potential market impact of this patent?
A: The patent’s claims support applications in diagnostics, drug discovery, and research, especially in high-throughput and automated systems, positioning the patent as relevant for companies in those sectors.
References:
[1] U.S. Patent and Trademark Office (USPTO). (2018). Patent No. 10,028,940.
[2] Prior art analysis based on publicly available patents and technology disclosures up to 2022.
